NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.
| Revenue (Most Recent Fiscal Year) | $99.99M |
| Net Income (Most Recent Fiscal Year) | $-21.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.44 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 37.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -21.67% |
| Net Margin (Trailing 12 Months) | -21.67% |
| Return on Equity (Trailing 12 Months) | -108.20% |
| Return on Assets (Trailing 12 Months) | -18.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.08 |
| Inventory Turnover (Trailing 12 Months) | 1.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.57 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 34.09M |
| Free Float | 27.11M |
| Market Capitalization | $541.41M |
| Average Volume (Last 20 Days) | 0.20M |
| Beta (Past 60 Months) | 1.88 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |